ArticleFrontiers in nutrition2026
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Metabolic syndrome (MetS) is a complex, multifactorial, systemic disease characterized by the coexistence of metabolic abnormalities and is clinically defined by the presence of at least three important risk factors: excess abdominal fat, a low serum concentration of high-density lipoprotein cholesterol, high serum triglyceride levels, high blood pressure, and high serum glucose levels. Understanding the role of epigenetics in MetS remains challenging because of the complexity of its multifactorial mechanisms. Thus, this study aimed to evaluate the factors associated with MetS and their association with methylation in the Methods: This cross-sectional study included 353 volunteers who were patients of the primary care service of the Brazilian Public Health System. Socioeconomic status, lifestyle, and health conditions were assessed, along with anthropometric measurements, blood pressure readings, and the collection of blood samples for biochemical and molecular analyses. The methylation levels of the promoter region (1F) of the Results: The prevalence of MetS was 40.5% in the present study, and factors associated with MetS in the multivariate Poisson regression were age, excess body fat, serum v Conclusion: In summary, these findings demonstrate a site-specific association between NR3C1 DNA methylation and MetS and highlight a molecular profile that coexists with established clinical risk factors. These results suggest a potential epigenetic role of the NR3C1 gene in MetS, contributing to a better understanding of its etiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.